Finance

Beta
Lists
BBOT:NASDAQ
BridgeBio Oncology Therapeutics Inc
$8.32
-8.47%
(-0.77) 1D
$8.39
+0.84% (+0.070)
After hours
Closed: Jul 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BBOT...
Open
$9.11
High
$9.24
Low
$8.30
Mkt. cap
665.87M
Avg. vol.
460.86K
Volume
389.51K
52-wk high
$14.87
52-wk low
$7.01
Shares outstanding
80.11M
No. of employees
106
Open
$9.11
High
$9.24
Low
$8.30
Mkt. cap
665.87M
Avg. vol.
460.86K
Volume
389.51K
52-wk high
$14.87
52-wk low
$7.01
Shares outstanding
80.11M
No. of employees
106
News stories
From sources across the web
About BridgeBio Oncology Therapeutics Inc
CEO-
Employees106
Founded2016
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitebbotx.com
Analyst ratings
Based on 8 analysts giving stock ratings to BBOT in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for BBOT in the last 3 months.
Highest
Current $8.32
$29.00 (+248.56%)
Average
$23.50 (+182.45%)
Lowest
$18.00 (+116.35%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
$23.00
+176.4%
07/08/2026
Unknown Analyst
J.P. Morgan
Buy
Initiated
$27.00
+224.5%
07/08/2026
Mazahir Alimohamed
Oppenheimer
Buy
Initiated
$22.00
+164.4%
06/22/2026
Biren Amin
Piper Sandler
Buy
Maintained
$21.00
+152.4%
06/01/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
$18.00
+116.3%
05/15/2026
David Nierengarten
Wedbush
Buy
Maintained
$25.00
+200.5%
05/13/2026
Laura Prendergast
Stifel Nicolaus
Buy
Maintained
$23.00
+176.4%
05/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$22.00
+164.4%
05/13/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$29.00
+248.6%
05/01/2026
Andrew Berens
Leerink Partners
Buy
Reiterated
$41.00
+392.8%
03/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27.44M
35.05M
38.07M
39.80M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.66M
14.13M
5.33M
6.38M
Operating expense
30.09M
49.18M
43.41M
46.18M
Total operating expenses
30.09M
49.18M
43.41M
46.18M
Operating income
-30.09M
-49.18M
-43.41M
-46.18M
Other non operating income
-8.00K
980.00K
187.00K
129.00K
EBT including unusual items
-28.44M
-44.76M
-38.80M
-42.11M
EBT excluding unusual items
-28.44M
-44.76M
-38.80M
-42.11M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-28.44M
-44.76M
-38.80M
-42.11M
Net profit margin
-
-
-
-
Earnings per share
-
-1.03
-0.49
-0.53
Interest and investment income
1.67M
3.44M
4.42M
3.94M
Interest expense
-
-
-
-
Net interest expenses
1.67M
3.44M
4.42M
3.94M
Depreciation and amortization charges
-
-
-
-
EBITDA
-30.02M
-49.11M
-43.32M
-46.10M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer